Free Trial!
Today’s Best Stocks To Trade! Click Here
Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. Regulation SHO mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.
Repros Therapeutics Inc. (NASDAQ: RPRX | news | PowerRating | PR Charts ) a development stage biopharmaceutical company, focuses on the development of drugs to treat hormonal and reproductive system disorders. The company's lead compound includes Proellex, a Phase II clinical trial product, for the treatment of uterine fibroids and endometriosis; and Androxal, a Phase III clinical trial product, which causes increased testosterone secretion from the testes, for the treatment of testosterone deficiency in men resulting from secondary hypogonadism. It also offers phentolamine-based products, such as VASOMAX for the treatment of male erectile dysfunction under the brand name, Z-Max, as well as Bimexes, an oral therapy for men with mild to moderate impotence, and ERxin, an injectable therapy for the treatment of severe erectile dysfunction. The company, formerly known as Zonagen, Inc., was founded in 1987 and changed its name to Repros Therapeutics, Inc. in 2006. Repros Therapeutics is based in The Woodlands, Texas. With 12.77 million shares outstanding and 1.39 million shares declared short as of January 2008, the failure to deliver in shares of RPRX has not been resolved and a buy-in is imminent.
Akesis Pharmaceuticals, Inc. (OTCBB: AKES | news | PowerRating | PR Charts ) a biopharmaceutical company, engages in the discovery, development, and commercialization of complementary and alternative therapies for the treatment of carbohydrate intolerance in the United States. Its products are used primarily in the treatment of three forms of carbohydrate intolerance, including Type II diabetes, Syndrome X, and impaired glucose tolerance and their associated complications. The company provides HEALTHPROPAK, a patented combination of micronutrients, which address health needs, health-maintenance issues, and aspects of general health and well-being. Akesis Pharmaceuticals product candidates in development comprise AKP-111, AKP-201, AKP-310, and AKP-411. The company was founded in 1990 and is based in La Jolla, California. With 22.58 million shares outstanding and an undisclosed short position, the failure to deliver in shares of AKES has not been resolved and a buy-in is possible.
PubliCARD, Inc. (OTC: CARD | news | PowerRating | PR Charts ) through its subsidiary, Infineer, Ltd., designs smart card solutions for educational and corporate sites in the United Kingdom and internationally. The company's products and solutions include ChipNet3 that delivers photo identification, payment for cafeteria, vending machine, photocopy and printing purchases, and access control applications on a single card platform; EasySmart, a solution that offers card acceptance for personal computer log-on, cafeteria point-of-sale, self-service centers, networked printing, photocopying, and encoding stations; and EasyCard product that delivers a flexible magnetic stripe-based solution for copying, printing, point-of-sale, vending, and Internet access applications. It also offers Pcounter, a network server-based print management and accounting solution for schools, colleges, professional services firms, the public sector, and corporations. PubliCARD, Inc. sells its products and solutions directly to end-users in the United Kingdom, as well as through resellers and distributors primarily in the United States, the Netherlands, France, and Australia. The company was founded in 1913 and is based in New York, New York. On May 17, 2007, Publicard, Inc filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York. With 24.94 million shares outstanding and an undisclosed short position, the failure to deliver in shares of CARD has not been resolved and a buy-in is possible.
Eden Energy Corp. (OTCBB: EDNE | news | PowerRating | PR Charts ) focuses on large scale oil and gas projects with significant resource potential. Its Noah project in eastern Nevada contains exceptionally rich source rocks, large thrusted fault blocks, and an excellent potential reservoir rock. The Chinchaga prospect in Northern Alberta also targets dolomitized Devonian reservoirs and its large resource potential fits well with the Company's goals. These high potential projects are balanced by the lower risk development project at White River Dome in Colorado. With 42.43 million shares outstanding and 241,000 shares declared short as of January 2008, the failure to deliver in shares of EDNE has not been resolved and a buy-in is imminent.
Intrepid Technology & Resources Inc (OTCBB: IESV | news | PowerRating | PR Charts ) together with its subsidiaries, operates as a biofuels renewable and alternative energy development and operating company in the United States. The company specializes in developing, constructing, operating, and owning or co-owning a portfolio of projects in the biofuels production and distribution area of the renewable energy sector. It focuses on the production of biofuels, such as biogas, biodiesel, ethanol, and hydrogen that are produced from biomass. It also provides consulting services in various science and technology disciplines, such as nuclear science, renewable energy, material science, construction management, soil science, crop management, and process engineering. In addition, the company offers a range of engineering services. Intrepid Technology & Resources, Inc. is headquartered in Idaho Falls, Idaho. With 246.77 million shares outstanding and 67,900 shares declared short as of January 2008, the failure to deliver in shares of IESV has not been resolved and a buy-in is imminent.
Maverick Oil and Gas Inc. (OTCBB: MVOG | news | PowerRating | PR Charts ) an independent energy company, engages in the exploration, exploitation, development, and production of oil and gas properties in the United States. It holds interest in the Fayetteville Shale project located in Woodruff County, Arkansas. The company was incorporated in 2002 and is based in Fort Lauderdale, Florida. With 118.14 million shares outstanding and 17,300 shares declared short as of January 2008, the failure to deliver in shares of MVOG has not been resolved and a buy-in is imminent.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 1,750,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, Buyins.net Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
